Critical Assessment of G Protein-Biased Agonism at the μ-Opioid Receptor

Area of Science:

• Pharmacology
• Neuroscience
• Medicinal Chemistry

Background:

• G protein-biased agonists of the micro-opioid receptor (MOPr) were proposed as novel analgesics.
• Recent studies challenge the reproducibility of original findings supporting this hypothesis.

Purpose of the Study:

• To evaluate the mechanistic basis and therapeutic potential of G protein-biased MOPr agonists.
• To address challenges in assessing ligand bias and its implications for drug development.

Main Methods:

• Re-evaluation of experimental data from β-arrestin2-knockout mouse models.
• Assessment of putatively biased ligands considering factors like assay amplification.
• Analysis of alternative genetic models to validate MOPr signaling pathways.

Main Results:

• Original findings supporting G protein-biased MOPr agonism could not be reproduced.
• Alternative genetic models did not support the G protein-biased MOPr agonist hypothesis.
• Assay amplification and other factors confounded the assessment of ligand bias.

Conclusions:

• The mechanistic novelty and extreme G protein-bias of current MOPr agonist lead compounds are uncertain.
• The assumption that β-arrestin2 mediates deleterious opioid effects requires further investigation.
• Addressing these challenges is critical for advancing MOPr drug development and improving opioid analgesics.